Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

NCT01469338 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT01469338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01469338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
November 30, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea, hormone-resistant prostate cancer, recurrent prostate cancer, stage i prostate cancer, stage iia prostate cancer, stage iib prostate cancer, stage iii prostate cancer, stage iv prostate cancer